3rd Quarter - Report

LINDE INC. for LINDE INC., LINDE, PLC AND OTHER ENTITIES RELATED TO LINDE, PLC

Firm
Client
Income
—
Expenses
$270,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Energy R&D funding; General international tax issues affecting U.S. based multinational corporations.

LobbyistCovered position, as disclosed
VALERIE KING —
SCOTT RUMMANS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Monitoring healthcare issues in House and Senate; S.882, Drug and Device Accountability Act of 2009. HR 3200, The America's Affordable Health Choices Act of 2009.

LobbyistCovered position, as disclosed
VALERIE KING —
SCOTT RUMMANS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 882 (111th), H.R. 3200 (111th)

Trade (domestic/foreign) TRD

General U.S. - Canada trade issues.

LobbyistCovered position, as disclosed
VALERIE KING —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Environment/Superfund ENV

American Clean Energy and Security Act of 2009 (ACES)

LobbyistCovered position, as disclosed
VALERIE KING —
SCOTT RUMMANS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Energy/Nuclear ENG

Energy R&D funding; increase and specify FUSRAP funding for the former Linde/Air Products site.

LobbyistCovered position, as disclosed
VALERIE KING —
SCOTT RUMMANS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.